ICML 2017 | Personalising treatment to the biology of the NHL patient

Graham Collins

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil from Oxford University Hospital, Oxford, UK gives us an overview of the sessions he particularly liked at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. He specifically liked the plenary session which was focussed on the EZH2 inhibitor, tazemetostat. Despite this therapy only being suitable for patients with a specific genetic aberration, it is proof of how the treatment of non-Hodgkin lymphoma (NHL) is moving towards being personalised to the biology of the patient. Small patient cohorts with high response rates is where research should go in the future. In addition, Dr Collins also mentions immunotherapy as another highlight, particularly as it is challenging the existing treatment paradigm. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video